血液科指南

订阅

MedSci主页 / 所有栏目 / 血液科指南

2021 SISET立场声明：Vaxzevria疫苗接种者血小板减少性静脉血栓形成的管理

2021-04-15 意大利血瘀血栓学会 Blood Transfus.2021 Apr 15.

静脉血栓形成

2021年4月，意大利血瘀血栓学会(SISET)针对之前接种过Vaxzevria疫苗者血小板减少性脑和内脏静脉血栓形成的管理发布了立场声明。Vaxzevria是一种抗COVID-19的疫苗，本文主要针

中文标题：

2021 SISET立场声明：Vaxzevria疫苗接种者血小板减少性静脉血栓形成的管理

英文标题：

Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis

发布机构：

意大利血瘀血栓学会

发布日期：

2021-04-15

简要介绍：

2021年4月，意大利血瘀血栓学会(SISET)针对之前接种过Vaxzevria疫苗者血小板减少性脑和内脏静脉血栓形成的管理发布了立场声明。Vaxzevria是一种抗COVID-19的疫苗，本文主要针对接种过该种疫苗者血小板减少性脑和内脏静脉血栓形成的管理提供指导建议。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=性脑和内脏静脉血栓形成的管理.pdf)] GetToolGuiderByIdResponse(projectId=1, id=b14d21c00209256a, title=2021 SISET立场声明：Vaxzevria疫苗接种者血小板减少性静脉血栓形成的管理, enTitle=Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis, guiderFrom=Blood Transfus.2021 Apr 15., authorId=0, author=, summary=2021年4月，意大利血瘀血栓学会(SISET)针对之前接种过Vaxzevria疫苗者血小板减少性脑和内脏静脉血栓形成的管理发布了立场声明。Vaxzevria是一种抗COVID-19的疫苗，本文主要针, cover=https://img.medsci.cn/202155/1620228580768_2020535.jpg, journalId=0, articlesId=null, associationId=431, associationName=意大利血瘀血栓学会, associationIntro=意大利关于血液学的学会，官方网站为意大利语。 出版物《溶栓系统的研究方法:先进研发室的摘要和论文》1993年英语发行。, copyright=0, guiderPublishedTime=Thu Apr 15 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年4月，意大利血瘀血栓学会(SISET)针对之前接种过Vaxzevria疫苗者血小板减少性脑和内脏静脉血栓形成的管理发布了立场声明。Vaxzevria是一种抗COVID-19的疫苗，本文主要针对接种过该种疫苗者血小板减少性脑和内脏静脉血栓形成的管理提供指导建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=12600, tagName=静脉血栓形成)], categoryList=[CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=92, categoryName=血管外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=12600, guiderKeyword=静脉血栓形成, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11773, appHits=91, showAppHits=0, pcHits=434, showPcHits=11682, likes=0, shares=43, comments=6, approvalStatus=1, publishedTime=Wed May 05 23:31:56 CST 2021, publishedTimeString=2021-04-15, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Wed May 05 23:31:10 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Tue Jan 02 10:17:59 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=性脑和内脏静脉血栓形成的管理.pdf)])
性脑和内脏静脉血栓形成的管理.pdf
下载请点击：
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1004613, encodeId=d3e11004613da, content=赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210802/5f5c0e7163464740bc5e2042b97ffa1f/dd2b0c2962de4cb396107777a06285ee.jpg, createdBy=4e7b2441913, createdName=123d84e1m24暂无昵称, createdTime=Mon Aug 02 12:45:26 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000544, encodeId=20be1000544d2, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210717/b785cfb3eb884441be9013f4d9691445/8b8267c7f87a4600a4c626fee5cef45e.jpg, createdBy=07385456548, createdName=菲诺, createdTime=Sun Jul 18 10:52:31 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964575, encodeId=46749645e5bc, content=已读，这真是触目惊心呀！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Tue May 11 13:55:20 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964344, encodeId=016c96434447, content=好文章！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon May 10 19:43:40 CST 2021, time=2021-05-10, status=1, ipAttribution=)]
    2021-08-02 123d84e1m24暂无昵称

    赞赞

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1004613, encodeId=d3e11004613da, content=赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210802/5f5c0e7163464740bc5e2042b97ffa1f/dd2b0c2962de4cb396107777a06285ee.jpg, createdBy=4e7b2441913, createdName=123d84e1m24暂无昵称, createdTime=Mon Aug 02 12:45:26 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000544, encodeId=20be1000544d2, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210717/b785cfb3eb884441be9013f4d9691445/8b8267c7f87a4600a4c626fee5cef45e.jpg, createdBy=07385456548, createdName=菲诺, createdTime=Sun Jul 18 10:52:31 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964575, encodeId=46749645e5bc, content=已读，这真是触目惊心呀！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Tue May 11 13:55:20 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964344, encodeId=016c96434447, content=好文章！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon May 10 19:43:40 CST 2021, time=2021-05-10, status=1, ipAttribution=)]
    2021-07-18 菲诺

    赞

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1004613, encodeId=d3e11004613da, content=赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210802/5f5c0e7163464740bc5e2042b97ffa1f/dd2b0c2962de4cb396107777a06285ee.jpg, createdBy=4e7b2441913, createdName=123d84e1m24暂无昵称, createdTime=Mon Aug 02 12:45:26 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000544, encodeId=20be1000544d2, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210717/b785cfb3eb884441be9013f4d9691445/8b8267c7f87a4600a4c626fee5cef45e.jpg, createdBy=07385456548, createdName=菲诺, createdTime=Sun Jul 18 10:52:31 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964575, encodeId=46749645e5bc, content=已读，这真是触目惊心呀！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Tue May 11 13:55:20 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964344, encodeId=016c96434447, content=好文章！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon May 10 19:43:40 CST 2021, time=2021-05-10, status=1, ipAttribution=)]
    2021-05-11 ms5000000518166734

    已读，这真是触目惊心呀！

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1004613, encodeId=d3e11004613da, content=赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210802/5f5c0e7163464740bc5e2042b97ffa1f/dd2b0c2962de4cb396107777a06285ee.jpg, createdBy=4e7b2441913, createdName=123d84e1m24暂无昵称, createdTime=Mon Aug 02 12:45:26 CST 2021, time=2021-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1000544, encodeId=20be1000544d2, content=赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210717/b785cfb3eb884441be9013f4d9691445/8b8267c7f87a4600a4c626fee5cef45e.jpg, createdBy=07385456548, createdName=菲诺, createdTime=Sun Jul 18 10:52:31 CST 2021, time=2021-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964575, encodeId=46749645e5bc, content=已读，这真是触目惊心呀！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Tue May 11 13:55:20 CST 2021, time=2021-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=964344, encodeId=016c96434447, content=好文章！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Mon May 10 19:43:40 CST 2021, time=2021-05-10, status=1, ipAttribution=)]
    2021-05-10 jyzxjiangqin

    好文章！

    0

拓展阅读

《欧洲血管外科学会（ESVS）2021年静脉血栓管理临床实践指南》临床热点解读

北京积水潭医院血管外科 · 2022-06-25

2022 NHS 临床指南：恶性肿瘤患者静脉血栓形成的治疗和二级预防 (178)

NHS 大格拉斯哥和克莱德 (NHSGGC) · 2022-05-12

2023 德国指南：静脉血栓形成和肺栓塞的诊断与治疗

德国血液学和肿瘤学学会(DGHO,German Society of Hematology and Oncology) · 2023-10-25